Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis

Based on extrapolation of similar clinical outcomes in rheumatoid arthritis to the originator infliximab (IFX) in randomized clinical trials, the first biosimilar antibody CT‐P13 was approved for the treatment of psoriasis. To evaluate the safety, efficacy, and drug survival of CT‐P13 for psoriasis...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Akimichi, Nishikawa, Kiyohiro, Yamada, Fumika, Yamanaka, Keiichi, Nakajima, Hideki, Ohtsuki, Mamitaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796256/
https://www.ncbi.nlm.nih.gov/pubmed/35799412
http://dx.doi.org/10.1111/1346-8138.16508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796256/
https://www.ncbi.nlm.nih.gov/pubmed/35799412
http://dx.doi.org/10.1111/1346-8138.16508

Ejemplares similares